{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:10:59Z","timestamp":1790813459656,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant progression such as bone metastasis, which is associated with pathologic fractures, pain and reduced survival frequently occurs in prostate cancer (PCa) patients at advanced stages. Accumulating evidence has supported that long non-coding RNAs (lncRNAs) participate in multiple biological processes. Nevertheless, the functions of most lncRNAs in PCa malignant progression remain largely unclear. Our current study is to elucidate the influence of lncRNA lncNAP1L6 on PCa malignant progression and uncover the possible regulatory mechanism. Firstly, RT-qPCR analysis was to detect lncNAP1L6 expression and suggested that lncNAP1L6 was markedly upregulated in PCa cells. Functional assays manifested that silencing of lncNAP1L6 hampered cell migration, invasion, and epithelial-mesenchymal transition (EMT) while overexpression of lncNAP1L6 exacerbated cell migration, invasion and EMT. In addition, mechanism assays were to determine the latent regulatory mechanism of lncNAP1L6. It turned out that METTL14\/METTL3 complex mediated m6A methylation of NAP1L2 mRNA. Besides, lncNAP1L6 recruited HNRNPC to m6A-modified NAP1L2, leading to stabilization of NAP1L2 mRNA. Moreover, NAP1L6 interacted with YY1 to promote the transcription of MMP2 and MMP9 and activate MMP signaling pathway. In summary, lncNAP1L6 was identified as an oncogene in PCa, which revealed that lncNAP1L6 might be used as potential therapeutic target in PCa.<\/jats:p>","DOI":"10.1038\/s41417-022-00537-3","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T11:04:26Z","timestamp":1664881466000},"page":"209-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["LncNAP1L6 activates MMP pathway by stabilizing the m6A-modified NAP1L2 to promote malignant progression in prostate cancer"],"prefix":"10.1038","volume":"30","author":[{"given":"Yuxiao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-9212","authenticated-orcid":false,"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4272","authenticated-orcid":false,"given":"Chao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-1136","authenticated-orcid":false,"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.semnuclmed.2016.07.002","volume":"46","author":"M Nguyen-Nielsen","year":"2016","unstructured":"Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 2016;46:484\u201390.","journal-title":"Semin Nucl Med"},{"key":"537_CR2","first-page":"184","volume":"28","author":"F Sata","year":"2001","unstructured":"Sata F, Umemura T, Kishi R. The epidemiology of prostate cancer-recent trends in prostate cancer incidence and mortality. Gan Kagaku Ryoho Cancer Chemother. 2001;28:184\u20138.","journal-title":"Gan Kagaku Ryoho Cancer Chemother"},{"key":"537_CR3","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jbmr.3618","volume":"33","author":"J Fornetti","year":"2018","unstructured":"Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. J Bone Miner Res. 2018;33:2099\u2013113.","journal-title":"J Bone Miner Res."},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mce.2009.07.004","volume":"310","author":"S Casimiro","year":"2009","unstructured":"Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol. 2009;310:71\u201381.","journal-title":"Mol Cell Endocrinol"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.job.2019.02.002","volume":"61","author":"T Hiraga","year":"2019","unstructured":"Hiraga T. Bone metastasis: interaction between cancer cells and bone microenvironment. J Oral Biosci. 2019;61:95\u201398.","journal-title":"J Oral Biosci"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gpb.2015.09.006","volume":"14","author":"Y Fang","year":"2016","unstructured":"Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteom Bioinf. 2016;14:42\u201354.","journal-title":"Genomics Proteom Bioinf."},{"key":"537_CR7","first-page":"11594","volume":"24","author":"P Peng","year":"2020","unstructured":"Peng P, Wang Y, Wang BL, Song YH, Fang Y, Ji H, et al. LncRNA PSMA3-AS1 promotes colorectal cancer cell migration and invasion via regulating miR-4429. Eur Rev Med Pharmacol Sci. 2020;24:11594\u2013601.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"537_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07441-9","volume":"20","author":"S Chen","year":"2020","unstructured":"Chen S, Li K. HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer. BMC Cancer. 2020;20:924.","journal-title":"BMC Cancer"},{"key":"537_CR9","doi-asserted-by":"crossref","unstructured":"Smolle MA, Bauernhofer T, Pummer K, Calin GA, Pichler M. Current insights into Long Non-Coding RNAs (LncRNAs) in prostate cancer. Int. J Mol Sci. 2017;18:473.","DOI":"10.3390\/ijms18020473"},{"key":"537_CR10","first-page":"74","volume":"24","author":"HY Li","year":"2020","unstructured":"Li HY, Jiang FQ, Chu L, Wei X. Long non-coding RNA BLACAT1 inhibits prostate cancer cell proliferation through sponging miR-361. Eur Rev Med Pharmacol Sci. 2020;24:74\u201385.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"537_CR11","first-page":"328","volume":"43","author":"R Hu","year":"2020","unstructured":"Hu R, Lu Z. Long non\u2011coding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR\u20114656 to modulate CEMIP expression. Oncol Rep. 2020;43:328\u201336.","journal-title":"Oncol Rep."},{"key":"537_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3892\/ol.2020.11958","volume":"20","author":"P He","year":"2020","unstructured":"He P, Xiong G, Guo W, Jiang G, Li Y, Li H. Long non-coding RNA CCAT2 promotes prostate cancer cell proliferation and invasion by regulating the Wnt\/\u03b2-catenin signaling pathway. Oncol Lett. 2020;20:97.","journal-title":"Oncol Lett"},{"key":"537_CR13","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.2147\/OTT.S163680","volume":"11","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Gao Y, Li X, Si S, Xu H, Qi F, et al. Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-\u03b2 A. OncoTargets Ther. 2018;11:4965\u201377.","journal-title":"OncoTargets Ther"},{"key":"537_CR14","doi-asserted-by":"crossref","unstructured":"Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-beta A [Corrigendum]. Onco Targets Ther. 2019;12:6563\u20134.","DOI":"10.2147\/OTT.S219868"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"536875","DOI":"10.3389\/fonc.2020.536875","volume":"10","author":"LC Wang","year":"2020","unstructured":"Wang LC, Chen SH, Shen XL, Li DC, Liu HY, Ji YL, et al. M6A RNA methylation regulator HNRNPC contributes to tumorigenesis and predicts prognosis in glioblastoma multiforme. Front Oncol. 2020;10:536875.","journal-title":"Front Oncol"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"e9589","DOI":"10.7717\/peerj.9589","volume":"8","author":"Z Tao","year":"2020","unstructured":"Tao Z, Zhao Y, Chen X. Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers. PeerJ. 2020;8:e9589.","journal-title":"PeerJ"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jgg.2013.10.002","volume":"41","author":"J Liu","year":"2014","unstructured":"Liu J, Jia G. Methylation modifications in eukaryotic messenger RNA. J Genet Genomics. 2014;41:21\u201333.","journal-title":"J Genet Genomics"},{"key":"537_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.2017021314","volume":"22","author":"W Wang","year":"2017","unstructured":"Wang W, Li D, Sui G. YY1 is an inducer of cancer metastasis. Crit Rev Oncog. 2017;22:1\u201311.","journal-title":"Crit Rev Oncog"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/path.4694","volume":"239","author":"FJ Tian","year":"2016","unstructured":"Tian FJ, Cheng YX, Li XC, Wang F, Qin CM, Ma XL, et al. The YY1\/MMP2 axis promotes trophoblast invasion at the maternal-fetal interface. J Pathol. 2016;239:36\u201347.","journal-title":"J Pathol"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"e0190725","DOI":"10.1371\/journal.pone.0190725","volume":"13","author":"F Yang","year":"2018","unstructured":"Yang F, Yu N, Wang H, Zhang C, Zhang Z, Li Y, et al. Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9. PLoS One. 2018;13:e0190725.","journal-title":"PLoS One"},{"key":"537_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/jcb.10664","volume":"91","author":"K Tantivejkul","year":"2004","unstructured":"Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem. 2004;91:706\u201317.","journal-title":"J Cell Biochem"},{"key":"537_CR22","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/febs.12902","volume":"281","author":"M Zhu","year":"2014","unstructured":"Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, et al. lncRNA H19\/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J. 2014;281:3766\u201375.","journal-title":"FEBS J"},{"key":"537_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13046-021-01891-0","volume":"40","author":"CY Hu","year":"2021","unstructured":"Hu CY, Chen J, Qin XH, You P, Ma J, Zhang J, et al. Long non-coding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancer. J Exp Clin Cancer Res 2021;40:98.","journal-title":"J Exp Clin Cancer Res"},{"key":"537_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63:306\u201317.","journal-title":"Mol Cell"},{"key":"537_CR25","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.1002\/jcp.28014","volume":"234","author":"Z Bi","year":"2019","unstructured":"Bi Z, Liu Y, Zhao Y, Yao Y, Wu R, Liu Q, et al. A dynamic reversible RNA N(6) -methyladenosine modification: current status and perspectives. J Cell Physiol. 2019;234:7948\u201356.","journal-title":"J Cell Physiol"},{"key":"537_CR26","doi-asserted-by":"publisher","first-page":"110339","DOI":"10.1016\/j.biopha.2020.110339","volume":"129","author":"Q You","year":"2020","unstructured":"You Q, Yao Y, Wu J, Cheng C, Li Y, Yuan H. YY1-induced lncRNA DSCR8 promotes the progression of ovarian cancer via miR-3192-5p\/YY1 axis. Biomed Pharmacother. 2020;129:110339.","journal-title":"Biomed Pharmacother"},{"key":"537_CR27","first-page":"589","volume":"34","author":"L Chen","year":"2019","unstructured":"Chen L, Gong X, Huang M. YY1-activated long noncoding RNA SNHG5 promotes glioblastoma cell proliferation through p38\/MAPK signaling pathway. Cancer Biother Radiopharm. 2019;34:589\u201396.","journal-title":"Cancer Biother Radiopharm"},{"key":"537_CR28","first-page":"519","volume":"34","author":"Y Ye","year":"2019","unstructured":"Ye Y, Gu B, Wang Y, Shen S, Huang W. YY1-induced upregulation of long noncoding RNA ARAP1-AS1 promotes cell migration and invasion in colorectal cancer through the Wnt\/\u03b2-Catenin signaling pathway. Cancer Biother Radiopharm. 2019;34:519\u201328.","journal-title":"Cancer Biother Radiopharm"},{"key":"537_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.18632\/genesandcancer.12","volume":"5","author":"V Kashyap","year":"2014","unstructured":"Kashyap V, Bonavida B. Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression. Genes Cancer. 2014;5:71\u201383.","journal-title":"Genes Cancer"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00537-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:04:19Z","timestamp":1673913859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00537-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1038\/s41417-022-00537-3","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}